IL-33: A potential therapeutic target in autoimmune diseases

Journal of Investigative Medicine

Volumn 60, Issue 8, 2012, Pages 1151-1156

  Wang, Song ^a   Ding, Lei ^a   Liu, Shan Shan ^a   Wang, Chao ^a   Leng, Rui Xue ^a   Chen, Gui Mei ^a   Fan, Yin Guang ^a   Pan, Hai Feng ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Autoimmune diseases; IL 33; ST2; Therapeutic target

Indexed keywords

INTERLEUKIN 33; INTERLEUKIN RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; ENTERITIS; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; INFLAMMATORY BOWEL DISEASE; MOLECULE; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 85006165393     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/jim.0b013e31826d8fcb     Document Type: Review

References (75)

1. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-490.
2. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187:787-794.
3. Beltrán CJ, Núñez LE, Díaz-Jiménez D, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;16:1097-1107.
4. Mangini AJ, Lafyatis R, Van Seventer JM. Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus. Ann N Y Acad Sci. 2007;1108:11-23.
5. Funauchi M, Ikoma S, Enomoto H, et al. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Rheumatol. 1998;27:219-224.
6. Horwitz DA, Gray JD, Behrendsen SC, et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 1998;41:838-844.
7. Esfandiari E, McInnes IB, Lindop G, et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol. 2001;167:5338-5347.
8. Ma L, Chan KW, Trendell-Smith NJ, et al. Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains. Eur J Immunol. 2005;35:3364-3375.
9. Onda H, Kasuya H, Takakura K, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 1999;19:1279-1288.
10. Boraschi D, Tagliabue A. The interleukin-1 receptor family. Vitam Horm. 2006;74:229-254.
11. Barksby HE, Lea SR, Preshaw PM, et al. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol. 2007;149:217-225.
12. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
13. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009;384:105-109.
14. Murphy GE, Xu D, Liew FY, McInnes IB. Role of interleukin 33 in human immunopathology. Ann Rheum Dis. 2010;69(suppl 1):i43-i47.
15. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A. 2007;104:282-287.
16. Allakhverdi Z, Smith DE, Comeau MR, et al. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 2007;179:2051-2054.
17. Verri WA Jr, Souto FO, Vieira SM, et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis. 2010;69:1697-1703.
18. Küchler AM, Pollheimer J, Balogh J, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008;173:1229-1242.
19. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PloS One. 2008;3:e3331.
20. Talabot-Ayer D, Lamacchia C, Gabay C, et al. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009;284:19420-19426.
21. Li H, Willingham SB, Ting JPY, et al. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol. 2008;181:17-21.
22. Hudson CA, Christophi GP, Gruber RC, et al. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol. 2008;84:631-633.
23. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-1549.
24. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A. 2009;106: 9021-9026.
25. Lüthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31:84-98.
26. Hayakawa M, Hayakawa H, Matsuyama Y, et al. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun. 2009;387:218-222.
27. Klemenz R, Hoffmann S, Werenskiold A. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci U S A. 1989;86:5708-5712.
28. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258:301-304.
29. Bergers G, Reikerstorfer A, Braselmann S, et al. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994;13:1176-1188.
30. Trajkovic V, Sweet MJ, Xu MJ. T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 2004;15:87-95.
31. Löhning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A. 1998;95:6930-6935.
32. Yanagisawa K, Takagi T, Tsukamoto T, et al. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 1993;318:83-87.
33. Yanagisawa K, Naito Y, Kuroiwa K, et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. J Biochem. 1997;121:95-103.
34. Gächter T, Werenskiold AK, Klemenz R. Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts. J Biol Chem. 1996;27:124-129.
35. Sweet MJ, Leung BP, Kang D, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol. 2001;166:6633-6639.
36. Tago K, Noda T, Hayakawa M, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun. 2001;285:1377-1383.
37. Towne JE, Garka KE, Renshaw BR, et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-{kappa} B and MAPKs. J Biol Chem. 2004;279:13677-13688.
38. Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008; 42:358-364.
39. Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179:2551-2555.
40. Ali S, Hubert M, Kollewe C, et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A. 2007;104:18660-18665.
41. Pushparaj PN, Tay HK, H'ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A. 2009;106:9773-9778.
42. Funakoshi-Tago M, Tago K, Hayakawa M, et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal. 2008;20:1679-1686.
43. Seidelin JB, Bjerrum JT, Coskun M, et al. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett. 2010;128:80-85.
44. Kobori A, Yagi Y, Imaeda H, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010;45:999-1007.
45. Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A. 2010;107:8017-8022.
46. Palmer G, Talabot-Ayer D, Lamacchia C, et al. Inhibition of interleukin33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60:738-749.
47. Leung BP, Xu D, Culshaw S, et al. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol. 2004; 173:145-150.
48. Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A. 2008;105:10913-10918.
49. Verri WA Jr, Guerrero AT, Fukada SY, et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci U S A. 2008;105:2723-2728.
50. Xu D, Jiang HR, Li Y, et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol. 2010;184:2620-2626.
51. Matsuyama Y, Okazaki H, Tamemoto H, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol. 2010;37:18-25.
52. Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZB9NZW) F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med. 1987;166:798-803.
53. Ozmen L, Roman D, Fountoulakis M, et al. Experimental therapy of systemic lupus erythematosus: the treatment of NZB W mice with mouse soluble interferon gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol. 1995;25:6-12.
54. Balomenos D, Rumold R, Theofilopoulos AN. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest. 1998;101:364-371.
55. Bourgeois E, Van LP, Samson M, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol. 2009;39:1046-1055.
56. Humphreys NE, Xu D, Hepworth MR, et al. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol. 2008;180:2443-2449.
57. Smithgall MD, Comeau MR, Yoon BR, et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK Cells. Int Immunol. 2008;20:1019-1030.
58. Mayuzumi N, Matsushima H, Takashima A. IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol. 2009;39:3331-3342.
59. Besnard AG, Togbe D, Guillou N, et al. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol. 2011;41:1675-1686.
60. Akahoshi M, Nakashima H, Tanaka Y, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum. 1999;42:1644-1648.
61. Nakashima H, Akahoshi M, Masutani K. Th1/Th2 balance of SLE patients with lupus nephritis. Rinsho Byori. 2006;54:706-713.
62. Shah K, Lee WW, Lee SH, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R53.
63. Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol. 2002;16:229-244.
64. Abbott NJ, Mendonça LL, Dolman DE. The blood-brain in systemic lupus erythematosus. Lupus. 2003;12:908-915.
65. Borchers AT, Aoki CA, Naguwa SM, et al. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev. 2005;4:329-344.
66. Iikuni N, Okamoto H, Yoshio T, et al. Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis. 2006;65:253-256.
67. Okamoto H, Iikuni N, Kamitsuji S, et al. IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients. Rheumatology. 2006;45:232-234.
68. Trysberg E, Nylen K, Rosengren LE, et al. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48:2881-2887.
69. Haga Y, Yanagisawa K, Ohto-Ozaki H, et al. The effect of ST2 gene product on anchorage-independent growth of a glioblastoma cell line, T98G. Eur J Biochem. 2003;270:163-170.
70. Mok MY, Huang FP, Ip WK, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology. 2010;49:520-527.
71. Yang Z, Liang Y, Xi W, et al. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med. 2011;11:75-80.
72. Manetti M, Ibba-Manneschi L, Liakouli V, et al. The IL-1-like cytokine IL-33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis. 2010;69:598-605.
73. Yanaba K, Yoshizaki A, Asano Y, et al. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol. 2011;30:825-830.
74. Theoharides TC, Zhang B, Kempuraj D, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A. 2010;107:4448-4453.
75. Li M, Li Y, Liu X, et al. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol. 2012;247:25-31.